Celcuity (CELC) Stock Highlights

9.36 | +0.75%

2025-04-03 06:10:04

Celcuity Inc is clinical-stage biotechnology company seeking to extend the lives of cancer patients by pursuing an integrated therapeutic (Rx) and companion diagnostic (CDx) strategy. The companys drug candidate, gedatolisib, is a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all class I isoforms of PI3K and mammalian target of rapamycin (mTOR).

Statistics

Range Today

8.75 9.48

Volume Today 645.1K

Range 1 Year

8.5 20.89

Volume 1 Year 73.36M

Range 3 Year

4.81 22.19

Volume 3 Year 118.15M

Range 10 Year

4.03 33.01

Volume 10 Year 173.33M

Highlights

Market Capitalization 380.21M (small)

Floating Shares 21.64M

Current Price 9.36

Price To Earnings -4.03

Price To Book 2.54

Earnings Per Share -2.6

Payout Ratio 0%

Performance

Latest +0.75%

1 Month -0.85%

3 Months -29.2%

6 Months -35.45%

1 Year -54.32%

3 Years +0.75%

5 Years +69.87%

10 Years -25.71%

Benchmarks

Market Capitalization

0 / 58

Gross Profits

0 / 52

Total Revenue

0 / 57

Total Rank

0 / 58

Free Cashflow

0 / 56

Performance 5 years

0 / 58

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.